Secondary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer: Case reports

Akihiko Wakayama, Wataru Kudaka, Tadaharu Nakasone, Yusuke Taira, Yoichi Aoki

Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan

ARTICLE INFO

Keywords:
Secondary uterine carcinosarcoma
Concurrent chemoradiotherapy
Cervical cancer

1. Introduction

Cervical cancer is the fourth most common cancer in women, with estimated 528,000 new cases and 266,000 deaths worldwide in 2012 (Cancer IAfRo, 2012). Advances in screening and treatments have improved prognoses in recent years. Cancer survivors, however, often live with long-term consequences of the disease and its treatment, including a higher risk of developing new primary cancers. This risk has been quantified to be 14% higher in cancer survivors in the U.S. as compared with the general population; particularly for cervical cancer survivors the risk was 32% (Curtis et al., 2006).

More than half of cervical cancer patients received initial radiotherapy (RT), either alone or in combination with a surgery. Therefore, several studies have reported a correlation between RT for cervical cancer and subsequent cancer risk. Significant lower risk was seen in patients with cancers of the breast and corpus uteri and melanoma of the skin (Curtis et al., 2006). During a follow-up study of 104,760 one-year survivors of cervical cancer, cases of the uterine corpus cancer did not show a statistically significant increase (Chaturvedi et al., 2007). A Japanese cohort study that enrolled 2167 cervical cancer patients who had underwent RT, showed no significant risk of secondary primary uterine malignancies (Ohno et al., 2007). Furthermore, a report from Japan in 5725 patients treated with radiation therapy showed that significant deficits of second cancer were observed in the uterus, colon, liver, and gallbladder (Arai et al., 1991).

On the other hand, Teng et al. reported that a significantly higher risk was observed for secondary cancers of the uterus (Teng et al., 2015). In a report from Japan, a site-based analysis revealed an excess of second cancers in the rectum and uterine body and occurrences of acute leukemia (Ota et al., 2007).

We found three cases of uterine carcinosarcoma as a secondly primary malignancy after concurrent chemoradiotherapy (CCRT) for cervical cancer, and report on these cases with a literature review.

2. Patients and methods

We retrospectively analyzed 313 patients with stage IB to IVA (18 patients in stage IB1, 39 IB2, 16 IIA, 132 IIB, 100 III, and 8 IVA) cervical cancer who were treated with CCRT between 1997 and 2013 at our hospital. None of the patients had received prior treatment. All patients provided written informed consent. Patient charts were reviewed for clinicopathological data and this was a contemporary cohort of patients. This retrospective study was approved by the Institutional Review Board of our university (#1043).

All patients were treated with anterior–posterior and posterior–anterior parallel–opposed ports, or with the four-field technique of whole-pelvic external beam radiotherapy (WP-EBRT). A 50-Gy dose of WP-EBRT was delivered in 25 fractions. A center shield (4-cm wide at the midline) was used in some patients after delivery of the 40-Gy dose. High-dose-rate intracavitary brachytherapy (HDR-ICBT) was delivered once per week at a fractional dose of 6 Gy that was given 1–3 times at point A for a total dose of 6–18 Gy. Boost EBRT doses of 6–20 Gy in 1–4 fractions were applied to the pelvic walls and/or nodal metastases (≥ 10 mm in a short-axis diameter) for patients with nodular parametrical involvement. The CCRT regimen consisted of cisplatin at 20 mg/m² for 5 days every 3 weeks or 40 mg/m² weekly, administered concomitantly with RT. Follow-up examinations were conducted every month for the first year, every 2 months for the second year, and every 3–6 months thereafter.

http://dx.doi.org/10.1016/j.gore.2017.07.008
Received 4 May 2017; Received in revised form 8 July 2017; Accepted 16 July 2017
Available online 17 July 2017
2352-5789/ © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
A. Wakayama et al.  Gynecologic Oncology Reports 21 (2017) 81–83

cisplatin, 20 mg/m² for 5 days) achieving a complete response. An ar-
carcinoma of the cervix stage IIA, and treated by CCRT (2 cycles of
died of the disease in 2 months.

A poor performance status due to the tumor and a past cerebral in-
di

specimen showed a uterine corpus carcinosarcoma comprising an un-
by ultrasound and computed tomography. The endometrial biopsy
of abdominal bulging, and was diagnosed with a uterine corpus tumor
years and 10 months after completion of the treatment, she complained
noma, and serous carcinoma (Fig. 1, right). She received six cycles of
endometrial stromal sarcoma, rhabdomyosarcoma, clear cell carci-
ectomy, and pelvic lymph node sampling. Histological examination
and magnetic resonance imaging (MRI) (Fig. 1, left). The patient un-
charge, and was diagnosed with a uterine corpus tumor by ultrasound

3. Results and case reports

Among these 313 patients, we found three cases (0.96%) with a
second uterine corpus malignancy after CCRT (Table 1).

In Case 1, a 50-year-old woman was diagnosed with squamous cell
 carcinoma of the cervix stage IIB and treated by CCRT (2 cycles of
cisplatin, 20 mg/m² for 5 days), achieving a complete response. After
6 years and 4 months’ post-treatment, she complained of vaginal dis-
charge, and was diagnosed with a uterine corpus tumor by ultrasound
and magnetic resonance imaging (MRI) (Fig. 1, left). The patient un-
derwent total abdominal hysterectomy, bilateral salpingo-oophore-
tomy, and pelvic lymph node sampling. Histological examination
revealed a uterine corpus carcinosarcoma that comprised a high grade
dometrial stromal sarcoma, rhabdomyosarcoma, clear cell carcino-
oma, and serous carcinoma (Fig. 1, right). She received six cycles of
paclitaxel and carboplatin postoperatively, but developed a recurrence
4 months later, and died of the disease 20 months after that.

In Case 2, a 70-year-old woman was diagnosed with squamous cell
carcinoma of the cervix stage IIB and treated by CCRT (2 cycles of
cisplatin, 20 mg/m² for 5 days), achieving a complete response. Nine
years and 10 months after completion of the treatment, she complained
of abdominal bulging, and was diagnosed with a uterine corpus tumor
by ultrasound and computed tomography. The endometrial biopsy
specimen showed a uterine corpus carcinosarcoma comprising an un-
derdifferentiated sarcoma and undifferentiated carcinoma. The patient had
a poor performance status due to the tumor and a past cerebral in-
farction; therefore, she was treated with the best supportive care. She
died of the disease in 2 months.

In Case 3, a 63-year-old woman was diagnosed with squamous cell
carcinoma of the cervix stage IIA, and treated by CCRT (2 cycles of
cisplatin, 20 mg/m² for 5 days) achieving a complete response. An
artifical anus was constructed due to radiation colitis after 3 years. Five
years and 8 months after completion of the treatment, she was diag-
nosed with a uterine corpus tumor using MRI (Fig. 2, left). Surgery was
performed, but it involved an exploratory laparotomy and endometrial
biopsy due to severe peritoneal carcinomatosis. Histological examina-
tion of the endometrial biopsy revealed carcinosarcoma that comprised
of osteosarcoma and clear cell carcinoma (Fig. 2, right). She died of the
disease after 4 months.

4. Discussion

Among 313 patients with a prior history of CCRT for cervical cancer
in our institute, 3 patients (0.96%) developed a primary second ma-
lignancy of the uterine corpus. The RT doses ranged from 58 to 64 Gy.
The latency time from the CCRT to the development of the carcino-
sarcoma ranged from 68 to 118 months, with a median of 76 months.
The median survival period from the secondary tumor occurrence was
4 months (range, 2–20 months). All the patients had heterologous carci-
osarcoma as the second uterine corpus malignancy. Therefore, post-
RT sarcoma should be discussed alongside cervical cancers. To consider
a RT-associated sarcoma, some criteria are proposed as follows: within
a previously irradiated field; a significant amount of radiation; a latency
period of several years (at least 3–5 years); and histologically proven
and different from the primary neoplasm (Cahan and Woodhard, 1948;
Arlet et al., 1971; Murray et al., 1999). Our cases satisfied the above-
mentioned criteria, although it cannot be completely ruled out that the
occurrence of uterine carcinosarcoma in these patients might be de
ovo.

Exposure to radiation has been long associated with increased risk of sarcoma and there has been considerable interest in identifying a
genetic expression profile that can differentiate between radiation-re-
lated and sporadic tumors. Although we did not complete chromosomal
and immunohistochemical examinations in our patients, the several
inspections for pathogenesis of RT-induced sarcoma have been reported
as follows: the loss of material from 3p21-3pter detected by compara-
tive genomic hybridization (Mertens et al., 2000), a role of p53 gene
mutations (Nakanishi et al., 1998), and the KIT protein overexpression
without mutation (Komdeur et al., 2003).

The uterine sarcoma mostly reported in patients treated with RT for
cervical cancer, and for benign conditions such as menorrhagia in early
reports. Duran et al. (1980) reported 9 patients with carcinosarcoma of
the uterus associated with a pelvic RT as compared with 8 non RT-
associated patients. Patients with post-RT tumors presented at a
younger age and with symptoms indicative of extensive intraabdominal
disease and two-thirds of the patient’s neoplasms were classified as

Table 1
Summary of three patients who developed second primary uterine malignancy.

| Age (years) | Latency (months) | Histology | Treatment | Survival |
|------------|-----------------|-----------|-----------|----------|
| 1          | 56              | 76        | CS (endometrial stromal sarcoma, rhabdomyosarcoma, clear cell carcinoma, serous carcinoma) | TAH + BSO + LN sampling, Paclitaxel + carboplatin | 20 months, DOD |
| 2          | 80              | 118       | CS (undifferentiated sarcoma, undifferentiated carcinoma) | Best supportive care | 2 months, DOD |
| 3          | 70              | 68        | CS (osteosarcoma, clear cell carcinoma) | Exploratory laparotomy | 4 months, DOD |

CS; carcinosarcoma, TAH; total abdominal hysterectomy, BSO; bilateral salpingo-oophorectomy, LN; lymph node, DOD; dead of disease.

Fig. 1. Magnetic resonance imaging T2-weighted sagittal image shows uterine cavity is occupied with high-intensity tumor (arrow) (left panel). Tumor cells comprise of high-grade endometrial stromal sarcoma (A), rhabdomyosarcoma (B), clear cell carcinoma (C), and serous carcinoma (D) (Hematoxylin-Eosin staining ×100) (right panel).

Fig. 2. Magnetic resonance imaging T2-weighted sagittal image shows uterine cavity is occupied with high-intensity tumor and hemorrhage (arrow) (left panel). Carcinosarcoma comprising of osteosarcoma (A) and clear cell carcinoma (B) (Hematoxylin-Eosin staining ×100) (right panel).
heterologous carcinosarcoma. The latent interval ranged from 9 to 30 years, with a median of 18 years. Mark et al. (1996) reported on 13 patients diagnosed with uterine sarcomas having a prior history of RT. The conditions for which these patients had received RT included one choriocarcinoma, four meningiomas, six cervical cancers, and two ovarian cancers. The RT doses ranged from 40 to 80 Gy and the latency time from the RT to the development of sarcoma ranged from 3 to 30 years, with a median of 17 years. The five-year disease-specific survival was 17%. The authors estimated that the absolute risk ranged from 0.03 to 0.8%. Arai et al. (1991) reported on 13 cases of second uterine cancer (0.023%) in patients after the RT, consisting of eight malignant mesotheliomas, three adenocarcinomas of the body, a leiomyosarcoma, and a rhabdomyosarcoma. The post-RT sarcoma of the gynecologic tract is a relatively late event associated with a poor prognosis. These findings were consistent with our cases.

Our patients were treated with anterior–posterior and posterior–anterior parallel–opposed ports, or with the four-field technique of WP-EBRT. Hall et al. summarized the new technologies, such as three-dimensional conformal radiation therapy (3D-CRT) and intensity-modulated radiation therapy (IMRT), on radiation-induced second cancers (Hall and Wu, 2003). 3D-CRT reduces the volume of normal tissues receiving a high dose, with an increase in dose to the target volume. A decrease in the number of second malignancy might be expected. IMRT involves more fields and the increased total body exposure, due to leakage radiation, leading to increased risk of second cancers. However, risk for subsequent uterine body malignancy remains unknown.

Secondary uterine corpus malignancies could develop > 5 years after the completion of CCRT, although it is a very rare event. Long-term follow-up data revealed that our method of CCRT for locally advanced carcinoma of the uterine cervix is effective, with a low incidence of second malignancies of the uterine corpus.

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgements

The authors would like to thank Enago (www.enago.jp) for the English language review.

References

Arai, T., Nakano, T., Fukushima, K., Kasamatsu, T., Tsunematsu, R., Masubuchi, K., Yamauchi, K., Hamada, T., Fukuda, T., Noguchi, H., Murata, M., 1991. Second cancer after radiation therapy for cancer of the uterine cervix. Cancer 67, 398–405.

Arden, M., Hignight, N.L., Hover, A.G., Marcover, R.C., Miller, T., Shah, I.C., 1971. Radiation induced sarcoma of bone. Cancer 28, 1087–1099.

Cahan, W.G., Woodhead, H.Q., 1948. Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1, 3–29.

Cancer IARo. 2012. Cervical Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp (Accessed April 30, 2017).

Chaturvedi, A.K., Engels, E.A., Gilbert, E.S., Chen, B.E., Storm, H., Lynch, C.F., Hall, P., Langmark, F., Pukkala, E., Kaijser, M., Andersson, M., Fosså, S.D., Jöenjuzu, H., Boice, J.D., Kleinerman, R.A., Travis, L.B., 2007. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J. Natl. Cancer Inst. 99, 1634–1643.

Curtis, R.E., Freedman, D.M., Ron, E., Ries, L.A.G., Hacker, D.G., Edwards, B.K., Tucker, M.A., Fraumeni, J.F., 2006. New Malignancies among Cancer Survivors: SEER Cancer Registrars, 1973–2000. National Cancer Institute, Bethesda (MD).

Durán, J.V., Nochomovitz, L.E., Prem, K.A., Dehner, L.P., 1980. Postirradiation mixed Mullerian tumors of the uterus. Cancer 45, 1625–1631.

Hall, E.J., Wuu, C.S., 2003. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int. J. Radiat. Oncol. Biol. Phys. 56, 83–88.

Komdeur, R., Hoekstra, H.J., Molenaar, W.M., Van Den Berg, E., Zwart, N., Pras, E., Plaza-Menacho, L., Hofstra, R.M., Van Der Graaf, W.T., 2003. Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target. Clin. Cancer Res. 9, 2926–2932.

Mark, R.J., Poen, J., Tran, L.M., Fu, Y.S., Heaps, J., Parker, R.G., 1996. Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies. Am. J. Clin. Oncol. 19, 59–64.

Mertens, F., Larramendy, M., Gustavsson, A., Gisselsson, D., Rydholm, A., Brojo, O., Mitelman, F., Knuutila, S., Mandahl, N., 2000. Radiation-associated sarcomas are characterized by complex karyotypes with frequent rearrangements of chromosome arm 3p. Cancer Genet. Cyto. 116, 89–96.

Murray, E.M., Werner, D., Greiff, E.A., Taylor, D.A., 1999. Postirradiation sarcomas: 20 cases and literature review. Int. J. Radiat. Oncol. Biol. Phys. 45, 951–961.

Nakazaki, H., Tomita, Y., Miyagi, A., Yoshikawa, H., Sakai, K., Kato, Y., Ochi, T., Aozasa, K., 1998. Mutations of the p53 gene in post irradiation sarcoma. Lab. Invest. 78, 727–733.

Ohno, T., Kato, S., Sato, S., Fukushima, K., Nakano, T., Tsujii, H., Arai, T., 2007. Long-term survival and risk of second cancers after radiotherapy for cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 69, 740–745.

Ota, T., Takeshima, N., Tabata, T., Hashmi, K., Takizawa, K., 2007. Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers. Br. J. Cancer 97, 1058–1062.

Teng, C.J., Huon, L.K., Hu, Y.W., Yeh, C.M., Chao, Y., Yang, M.H., Chen, T.J., Hung, Y.P., Liu, C.J., 2015. Secondary primary malignancy risk in patients with cervical cancer in Taiwan: a Nationwide population-based study. Med. (Baltimore) 94, e1803.